References
- American Diabetes Association. Report of the expert committees on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183–1197
- Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999; 22: 920–924
- Crook MA, Goldsmith L, Ameerally P, Lumb P, Singh N, Miell J, Russell-Jones D. Serum sialic acid, a possible cardiovascular risk factor is not increased in Fijian Melanesians with impaired glucose tolerance or impaired fasting glucose. Ann Clin Biochem 2002; 39: 606–608
- Bjørnholt JV, Erikssen G, Aaser E, Sandvik L, Nitter-Hauge S, Jervell J, Erikssen J, Thaulow E. Fasting blood glucose: An underestimated risk factor for cardiovascular death. Results from a 22-year follow-up of healthy diabetic men. Diabetes Care 1999; 22: 45–49
- Balkau B, Bertrais S, Ducimetiere P, Eschwege E. Is there a glycemic threshold for mortality risk?. Diabetes Care 1999; 22: 696–699
- Scheidt-Nave C, Barrett-Connor E, Wingard DL, Cohn BA, Edelstein SL. Sex differences in fasting glycemia as a risk factor for ischaemic heart disease death. Am J Epidemiol 1991; 133: 565–576
- Weitzman S. Impaired fasting glucose is not a risk factor for cardiovascular mortality. Diabetes Care 1999; 22: 2104
- Henry P, Thomas F, Benetos A, Guize L. Impaired Fasting glucose blood pressure and cardiovascular mortality. Hypertension 2002; 40: 458–463
- DECODE study (Diabetes epidemiology: Collaborative analysis of diagnostic criteria in Europe). Diabetes Care 1999; 22: 1667–1171, Consequences of the new diagnostic criteria for diabetes in older men and women
- Kristensen SD. The platelet-vessel wall interaction in experimental atherosclerosis and ischaemic heart disease with special reference to thrombopoiesis. Dan Med Bull 1992; 39: 110–127
- Bath PM, Carney C, Markandu ND, MacGregor GA. Platelet volume is not increased in essential hypertension. J Hum Hypertens 1994; 8: 457–459
- Park Y, Schoene N, Harris W. Mean platelet volume as an indicator of platelet activation: Methodological issues. Platelets 2002; 13: 301–306
- Brown AS, Hong Y, de Belder A, Beacon H, Beeso J, Sherwood R, Edmonds M, Martin JF, Erusalimsky JD. Megakaryocyte ploidy and platelet changes in human diabetes and atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 802–807
- Sharpe PC, Trinick T. Mean platelet volume in diabetes mellitus. Q J Med 1993; 86: 739–742
- Tschope D, Langer E, Schauseil S, Rosen P, Kaufmann L, Gries FA. Increased platelet volume – sign of impaired thrombopoiesis in diabetes mellitus. Klin Wochenschr 1989; 67: 253–259
- Hekimsoy Z, Payzin B, Ornek T, Kandogan G. Mean platelet volume in type 2 diabetic patients. J Diabetes Complications 2004; 18: 173–176
- Erhart S, Beer JH, Reinhart WH. Influence of aspirin on platelet count and volume in humans. Acta Haematol 1999; 101: 140–144
- Thompson CB, Jakubowski JA. The pathophysiology and clinical relevance of platelet heterogeneity. Blood 1988; 72: 1–8
- Inui Y, Suehiro T, Kumon Y, Hashimoto K. Platelet volume and urinary prostanoid metabolites in non-insulin-dependent diabetes mellitus. J Atheroscler Thromb 1994; 1: 108–112